Coronavirus channel feed

GSK, Ger­many push coro­n­avirus-fo­cused mR­NA play­er Cure­Vac's lat­est round to $640M

5 years ago
Financing

Not just As­traZeneca — CanSi­no Bi­o­log­ics al­so un­veils Phase II da­ta, show­ing an­ti­body and T cell re­sponse

5 years ago
R&D

As­traZeneca, Ox­ford re­searchers cham­pi­on a one-two punch against Covid-19 in first hu­man study

5 years ago
R&D

Covid-19 roundup: Fau­ci push­es back on Mer­ck’s Fra­zier; Pfiz­er un­veils first vac­cine sup­ply deal as UK nabs 90M more dos­es

5 years ago

UK biotech rock­ets up on Covid-19 'break­through' for in­haled in­ter­fer­on be­ta — can its small study live up to the boast?

5 years ago
R&D

Covid-19 roundup: EU looks to pre-or­der vac­cines from Mod­er­na, Sanofi, J&J, BioN­Tech, Cure­Vac — re­port

5 years ago

Covid-19 roundup: Rus­sia hack­ers tar­get US, UK vac­cine and drug re­searchers; Fau­ci fires back at White House cam­paign to un­der­mine him

5 years ago

A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta

5 years ago
R&D

‘Plan­ning to vac­ci­nate every­one in the US,’ Mod­er­na out­lines ef­forts to sup­ply their Covid-19 vac­cine as man­u­fac­tur­ing ramps up ahead of PhI­II

5 years ago

Ex­perts urge trans­paren­cy, ad­vi­so­ry com­mit­tee re­view for Covid-19 vac­cines

5 years ago
FDA+

Covid-19 roundup: Vac­cine by end of 2020? Ken Fra­zier warns hype do­ing 'grave dis­ser­vice'

5 years ago

NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main to be an­swered

5 years ago
R&D

Covid-19 roundup: Af­ter Trump at­tack, doc­tors, re­searchers flock to de­fend Fau­ci; Philip Mor­ris-backed Med­ica­go be­gins dos­ing to­bac­co-based vac­cine

5 years ago

More Warp Speed con­tracts com­ing, vac­cine pro­duc­tion to be­gin in 4-6 weeks — of­fi­cials

5 years ago

White House tries to dis­cred­it An­tho­ny Fau­ci — could he be on his way out?

5 years ago
People

A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA

5 years ago
Bioregnum
Opinion

Covid-19 roundup: CanSi­no eyes more over­seas PhI­II sites as Cana­da tri­al re­port­ed­ly stalls; In­di­an drug­mak­er surges on 30-per­son da­ta

5 years ago
R&D

Gilead boasts of pos­i­tive remde­sivir da­ta on mor­tal­i­ty — but their analy­sis pro­vokes the skep­tics

5 years ago
R&D

Pe­ter Marks on Covid-19 vac­cine ef­fi­ca­cy, EUAs and chal­lenge tri­als

5 years ago
FDA+

Covid-19 roundup: BioN­Tech go­ing head-to-head with Mod­er­na as PhI­II mR­NA launch looms; Tri­al on Shin­zo Abe’s once-fa­vorite an­tivi­ral is in­con­clu­sive

5 years ago

NIH kicks off Covid-19 vac­cine, mon­o­clon­al an­ti­body re­search net­work

5 years ago

Covid-19 roundup: CDC de­bat­ing who should get first avail­able vac­cines; EU in Gilead talks af­ter US gob­bled first remde­sivir dos­es

5 years ago

A new study points to $6.5B in pub­lic sup­port build­ing the sci­en­tif­ic foun­da­tion of Gilead­'s remde­sivir. Should that be re­flect­ed in the price?

5 years ago
Bioregnum
R&D

Covid-19 roundup: Mod­er­na sticks to Ju­ly for its Phase III as ru­mors swirl; Fol­low­ing US lead, EU buys up Covid-19 treat­ments

5 years ago
First page Previous page 47484950515253 Next page Last page
A service from the Financial Times